Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert J Augustin

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|September 19, 2017
Semifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease Due to Meibomian Gland DiseasePhilipp Steven, Albert J Augustin, Gerd Geerling, et al.
Ophthalmologica. Journal International D'Ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde|December 16, 2014
Retrospective, observational study in patients receiving a dexamethasone intravitreal implant 0.7 mg for macular oedema secondary to retinal vein occlusionAlbert J Augustin, Frank G Holz, Christos Haritoglou, et al.
Eye (London, England)|July 20, 2019
Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I dataSrinivas R Sadda, Joanna Campbell, Pravin U Dugel, et al.
American Journal of Ophthalmology|March 27, 2017
ReplyVictor H Gonzalez, Joanna Campbell, Nancy M Holekamp, et al.
American Journal of Ophthalmology|September 21, 2016
Early and Long-Term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I DataVictor H Gonzalez, Joanna Campbell, Nancy M Holekamp, et al.
Retina (Philadelphia, Pa.)|February 24, 2018
ASSOCIATION BETWEEN EARLY ANATOMIC RESPONSE TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND LONG-TERM OUTCOME IN DIABETIC MACULAR EDEMA: An Independent Analysis of Protocol i Study DataPravin U Dugel, Joanna H Campbell, Szilárd Kiss, et al.
European Journal of Ophthalmology|March 20, 2019
Three-year results from the Retro-IDEAL study: Real-world data from diabetic macular edema (DME) patients treated with ILUVIEN<sup>®</sup> (0.19 mg fluocinolone acetonide implant)Albert J Augustin, Silvia Bopp, Martin Fechner, et al.
European Journal of Ophthalmology|May 5, 2021
The impact of vitrectomy on outcomes achieved with 0.19 mg fluocinolone acetonide implant in patients with diabetic macular edemaAlbert J Augustin, Silvia Bopp, Martin Fechner, et al.
Klinische Monatsblatter Fur Augenheilkunde|June 17, 2020
[Correction: Safety, Efficacy and Protective Aspects of an Add-on Paracentesis during Intravitreal Injections]Michael Janusz Koss, Matthias Bolz, Albert J Augustin, et al.
Klinische Monatsblatter Fur Augenheilkunde|November 27, 2019
[Safety, Efficacy and Protective Aspects of an Add-on Paracentesis during Intravitreal Injections]Michael Janusz Koss, Matthias Bolz, Albert J Augustin, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|September 19, 2017
Semifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease Due to Meibomian Gland DiseasePhilipp Steven, Albert J Augustin, Gerd Geerling, et al.
Ophthalmologica. Journal International D'Ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde|December 16, 2014
Retrospective, observational study in patients receiving a dexamethasone intravitreal implant 0.7 mg for macular oedema secondary to retinal vein occlusionAlbert J Augustin, Frank G Holz, Christos Haritoglou, et al.
Eye (London, England)|July 20, 2019
Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I dataSrinivas R Sadda, Joanna Campbell, Pravin U Dugel, et al.
American Journal of Ophthalmology|March 27, 2017
ReplyVictor H Gonzalez, Joanna Campbell, Nancy M Holekamp, et al.
American Journal of Ophthalmology|September 21, 2016
Early and Long-Term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I DataVictor H Gonzalez, Joanna Campbell, Nancy M Holekamp, et al.
Retina (Philadelphia, Pa.)|February 24, 2018
ASSOCIATION BETWEEN EARLY ANATOMIC RESPONSE TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND LONG-TERM OUTCOME IN DIABETIC MACULAR EDEMA: An Independent Analysis of Protocol i Study DataPravin U Dugel, Joanna H Campbell, Szilárd Kiss, et al.
European Journal of Ophthalmology|March 20, 2019
Three-year results from the Retro-IDEAL study: Real-world data from diabetic macular edema (DME) patients treated with ILUVIEN<sup>®</sup> (0.19 mg fluocinolone acetonide implant)Albert J Augustin, Silvia Bopp, Martin Fechner, et al.
European Journal of Ophthalmology|May 5, 2021
The impact of vitrectomy on outcomes achieved with 0.19 mg fluocinolone acetonide implant in patients with diabetic macular edemaAlbert J Augustin, Silvia Bopp, Martin Fechner, et al.
Klinische Monatsblatter Fur Augenheilkunde|June 17, 2020
[Correction: Safety, Efficacy and Protective Aspects of an Add-on Paracentesis during Intravitreal Injections]Michael Janusz Koss, Matthias Bolz, Albert J Augustin, et al.
Klinische Monatsblatter Fur Augenheilkunde|November 27, 2019
[Safety, Efficacy and Protective Aspects of an Add-on Paracentesis during Intravitreal Injections]Michael Janusz Koss, Matthias Bolz, Albert J Augustin, et al.
Pageof 6